Back to Archived Journals » Biosimilars » Volume 1

Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics

Authors Chow S, Endrenyi L, Lachenbruch, Yang, Chi

Published 16 June 2011 Volume 2011:1 Pages 13—26

DOI https://doi.org/10.2147/BS.S20577

Review by Single-blind

Peer reviewer comments 2


Shein-Chung Chow1, Laszlo Endrenyi2, Peter A Lachenbruch3, Lan-Yan Yang1, Eric Chi4
1Duke University School of Medicine, Durham, NC, USA; 2University of Toronto, Toronto, Canada; 3Oregon State University, Corvallis, OR, USA; 4Amgen, Inc, Thousand Oaks, CA, USA

Abstract: Biological products are therapeutic agents produced using a living system or organism. In practice, access to these life-saving biological products is limited due to their expensive cost. In the next few years, patents of the early biological products will expire. This provides other biopharmaceutical/biotech companies the opportunity to manufacture follow-on biologics. For the conventional pharmaceuticals of small molecules, regulations and statistical methods for the assessment of bioequivalence for generic approval are well established. However, unlike the conventional drug products, the complexity and heterogeneity of the molecular structure, complicated manufacturing process, different analytical methods, and the possibility of severe immunogenicity reactions make evaluation of equivalence (similarity) between an innovator and its follow-on biologics a great challenge for both the scientific community and regulatory agencies. This article reviews past experiences for the assessment of bioequivalence for conventional drug products. Detailed descriptions of the fundamental differences and assumptions between the chemical generic products and follow-on biologics are given. An overview of current regulatory requirements for assessing biosimilarity of follow-on biologics is provided. Statistical considerations for scientific factors for assessing biosimilarity and drug interchangeability of the follow-on biologics as posted at the recent FDA Public Hearing on Approval Pathway for Biosimilar and Interchangeability Biological Products are discussed. In addition, current statistical issues that are commonly encountered when assessing biosimilarity of follow-on biologics are reviewed.

Keywords: bioequivalence, biosimilarity, drug interchangeability, alternating, switching, replicated design, biosimilarity index

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]